Elsiglutide: Phase IIb data

Top-line data from a double-blind, European Phase IIb trial in 497 colorectal cancer patients receiving 5-fluorouracil (5-FU) showed that once-daily subcutaneous elsiglutide missed

Read the full 232 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE